Which has higher valuation & earnings, SMMT or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is SMMT or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Enliven Therapeutics N/A -21.04% -20.41%

Does the media prefer SMMT or ELVN?

In the previous week, Enliven Therapeutics had 7 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Enliven Therapeutics and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.50 beat Enliven Therapeutics' score of 1.26 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELVN or ELAN?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Enliven Therapeutics and 5 mentions for Elanco Animal Health. Enliven Therapeutics' average media sentiment score of 1.26 beat Elanco Animal Health's score of 1.03 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or ELVN?

In the previous week, Arrowhead Pharmaceuticals had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 11 mentions for Arrowhead Pharmaceuticals and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.26 beat Arrowhead Pharmaceuticals' score of 0.82 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELVN or RDY?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Enliven Therapeutics and 5 mentions for Dr. Reddy's Laboratories. Enliven Therapeutics' average media sentiment score of 1.26 beat Dr. Reddy's Laboratories' score of 0.08 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ELVN or ABVX?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is ELVN or ABVX more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Abivax N/A -99.02% -70.26%

Does the media favor ELVN or ABVX?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Enliven Therapeutics and 5 mentions for Abivax. Enliven Therapeutics' average media sentiment score of 1.26 beat Abivax's score of 1.07 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enliven Therapeutics (ELVN) Competitors

$52.11 +1.25 (+2.46%)

As of 10:10 AM Eastern

Compare

ELVN vs. SMMT, ELAN, ARWR, RDY, and ABVX

Should you buy Enliven Therapeutics stock or one of its competitors? MarketBeat compares Enliven Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enliven Therapeutics include Summit Therapeutics (SMMT), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Dr. Reddy's Laboratories (RDY), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Enliven Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Enliven Therapeutics had 7 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Enliven Therapeutics and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.50 beat Enliven Therapeutics' score of 1.26 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Enliven Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics presently has a consensus target price of $26.97, indicating a potential upside of 95.09%. Enliven Therapeutics has a consensus target price of $69.17, indicating a potential upside of 32.73%. Given Summit Therapeutics' higher possible upside, equities research analysts plainly believe Summit Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summit Therapeutics has a beta of -1.26, indicating that its share price is 226% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Enliven Therapeutics' return on equity of -21.04% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Summary

Enliven Therapeutics beats Summit Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Enliven Therapeutics compare to Elanco Animal Health?

Enliven Therapeutics (NASDAQ:ELVN) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Enliven Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Elanco Animal Health	-4.95%	7.42%	3.66%

Enliven Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Elanco Animal Health	$4.72B	2.77	-$232M	-$0.50	N/A

Enliven Therapeutics presently has a consensus price target of $69.17, indicating a potential upside of 32.73%. Elanco Animal Health has a consensus price target of $28.55, indicating a potential upside of 9.22%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Enliven Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Enliven Therapeutics had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Enliven Therapeutics and 5 mentions for Elanco Animal Health. Enliven Therapeutics' average media sentiment score of 1.26 beat Elanco Animal Health's score of 1.03 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enliven Therapeutics beats Elanco Animal Health on 8 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Enliven Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Enliven Therapeutics' return on equity of -21.04% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Arrowhead Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 11 mentions for Arrowhead Pharmaceuticals and 9 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.26 beat Arrowhead Pharmaceuticals' score of 0.82 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Enliven Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.61	-$1.63M	-$2.15	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Arrowhead Pharmaceuticals currently has a consensus price target of $88.17, suggesting a potential upside of 18.72%. Enliven Therapeutics has a consensus price target of $69.17, suggesting a potential upside of 32.73%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Enliven Therapeutics beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Dr. Reddy's Laboratories?

Enliven Therapeutics (NASDAQ:ELVN) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Dr. Reddy's Laboratories has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Dr. Reddy's Laboratories	$3.58B	2.97	$456M	$0.58	21.95

Enliven Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Enliven Therapeutics currently has a consensus price target of $69.17, indicating a potential upside of 32.73%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enliven Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Enliven Therapeutics had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Enliven Therapeutics and 5 mentions for Dr. Reddy's Laboratories. Enliven Therapeutics' average media sentiment score of 1.26 beat Dr. Reddy's Laboratories' score of 0.08 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Enliven Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Summary

Enliven Therapeutics and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to Abivax?

Enliven Therapeutics (NASDAQ:ELVN) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Enliven Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Enliven Therapeutics and 5 mentions for Abivax. Enliven Therapeutics' average media sentiment score of 1.26 beat Abivax's score of 1.07 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Enliven Therapeutics presently has a consensus target price of $69.17, indicating a potential upside of 32.73%. Abivax has a consensus target price of $148.54, indicating a potential upside of 8.42%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Enliven Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Abivax	N/A	-99.02%	-70.26%

Enliven Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Summary

Enliven Therapeutics beats Abivax on 11 of the 14 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELVN vs. The Competition

Export

Metric	Enliven Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.17B	$3.02B	$6.91B	$12.20B
Dividend Yield	N/A	2.09%	2.68%	8.87%
P/E Ratio	-31.18	19.88	27.23	23.90
Price / Sales	N/A	801.63	573.53	111.21
Price / Cash	N/A	56.84	49.25	59.89
Price / Book	6.73	4.24	10.85	6.19
Net Income	-$103.69M	$65.46M	$3.59B	$331.84M
7 Day Performance	2.00%	-3.46%	-2.26%	-2.30%
1 Month Performance	16.16%	0.38%	1.89%	-1.63%
1 Year Performance	123.26%	16.62%	23.86%	16.11%

Enliven Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELVN Enliven Therapeutics	3.4473 of 5 stars	$52.11 +2.5%	$69.17 +32.7%	+137.0%	$3.17B	N/A	N/A	50	Positive News
SMMT Summit Therapeutics	3.6685 of 5 stars	$15.88 -0.3%	$26.97 +69.9%	-51.3%	$12.33B	N/A	N/A	110	Positive News Analyst Forecast
ELAN Elanco Animal Health	3.6675 of 5 stars	$24.64 -2.0%	$28.55 +15.9%	+78.9%	$12.31B	$4.72B	N/A	9,400	Positive News
ARWR Arrowhead Pharmaceuticals	3.4217 of 5 stars	$86.97 +0.5%	$87.27 +0.3%	+290.1%	$12.25B	$622.01M	N/A	400	Analyst Forecast
RDY Dr. Reddy's Laboratories	1.8884 of 5 stars	$14.65 +2.0%	N/A	-13.0%	$12.22B	$3.58B	25.25	27,527	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELVN) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Competitors

ELVN vs. SMMT, ELAN, ARWR, RDY, and ABVX

How does Enliven Therapeutics compare to Summit Therapeutics?

Summary

How does Enliven Therapeutics compare to Elanco Animal Health?

Summary

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Enliven Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Enliven Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enliven Therapeutics (ELVN) Competitors

ELVN vs. SMMT, ELAN, ARWR, RDY, and ABVX

How does Enliven Therapeutics compare to Summit Therapeutics?

Does the media prefer SMMT or ELVN?

Do analysts recommend SMMT or ELVN?

Which has more risk and volatility, SMMT or ELVN?

Do insiders and institutionals believe in SMMT or ELVN?

Is SMMT or ELVN more profitable?

Which has higher valuation & earnings, SMMT or ELVN?

Summary

How does Enliven Therapeutics compare to Elanco Animal Health?

Which has more risk & volatility, ELVN or ELAN?

Is ELVN or ELAN more profitable?

Which has higher valuation & earnings, ELVN or ELAN?

Do analysts prefer ELVN or ELAN?

Do institutionals and insiders believe in ELVN or ELAN?

Does the media favor ELVN or ELAN?

Summary

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Is ARWR or ELVN more profitable?

Which has more risk & volatility, ARWR or ELVN?

Does the media favor ARWR or ELVN?

Do insiders and institutionals hold more shares of ARWR or ELVN?

Which has higher valuation & earnings, ARWR or ELVN?

Do analysts rate ARWR or ELVN?

Summary

How does Enliven Therapeutics compare to Dr. Reddy's Laboratories?

Which has better valuation & earnings, ELVN or RDY?

Which has more risk & volatility, ELVN or RDY?

Do analysts rate ELVN or RDY?

Do institutionals and insiders believe in ELVN or RDY?

Does the media refer more to ELVN or RDY?

Is ELVN or RDY more profitable?

Summary

How does Enliven Therapeutics compare to Abivax?

Do institutionals & insiders have more ownership in ELVN or ABVX?

Does the media favor ELVN or ABVX?

Which has higher earnings and valuation, ELVN or ABVX?

Do analysts prefer ELVN or ABVX?

Is ELVN or ABVX more profitable?

Which has more volatility and risk, ELVN or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools